Whitehawk Therapeutics, Inc. Market Cap ($141.39 Million)
Market Cap & Net Worth: Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. market cap. Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has a market capitalization of $141.39 Million ($141.39 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17683 globally and #4190 in its home market, demonstrating a -1.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Whitehawk Therapeutics, Inc.'s stock price $3.10 by its total outstanding shares 47128362 (47.13 Million). Also see how efficiently does Whitehawk Therapeutics, Inc. generate cash for how efficiently the company converts equity into cash flow.
Whitehawk Therapeutics, Inc. Market Cap History (2025–2026)
Whitehawk Therapeutics, Inc. market cap history from 2025 to 2026. Data shows growth from $114.05 Million to $146.10 Million (32.60% CAGR). Check current stock price of Whitehawk Therapeutics, Inc. for real-time trading data and today's change.
Index Memberships
Whitehawk Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #482 of 976 |
Weight: Whitehawk Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Whitehawk Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Whitehawk Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Whitehawk Therapeutics, Inc. annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of WHWK by Market Capitalization
Companies near Whitehawk Therapeutics, Inc. in the global market cap rankings as of November 5, 2026. Also see WHWK total assets for a full breakdown of the balance sheet.
Key companies related to Whitehawk Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Whitehawk Therapeutics, Inc. (2025–2026)
Market capitalization of Whitehawk Therapeutics, Inc. from 2025 to today. Between 2025 and today, Whitehawk Therapeutics, Inc.'s market cap moved from $114.05 Million to $ 146.10 Million, with a yearly change of 32.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $146.10 Million | +28.10% |
| 2025 | $114.05 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Whitehawk Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $141.39 Million USD |
| MoneyControl | $141.39 Million USD |
| MarketWatch | $141.39 Million USD |
| marketcap.company | $141.39 Million USD |
| Reuters | $141.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more